Inactive Instrument

Aradigm Corporation OTC Bulletin Board

Equities

ARDM

US0385053014

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2020	Aradigm Corporation Went Out of Business	CI
2020	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Aradigm Corporation : Aradigm to Present at Biotech Showcase 2012 on January 9

January 05, 2012 at 01:10 pm EST

MarketScreener.com By

Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at Biotech Showcase 2012 on Monday, January 9, 2012, at 11: 00 a.m. Pacific time. The event will be held at Parc 55 Wyndham - Union Square Hotel, San Francisco, California.

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 14 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

Latest news about Aradigm Corporation

Aradigm Corporation Went Out of Business	20-06-29	CI
Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	20-06-12	CI
Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	20-04-27	CI
Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	20-04-08	CI
Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	20-03-30	CI
Motion for Asset Sale Approved for Aradigm Corporation	20-03-30	CI
Bidding Procedure Approved for Aradigm Corporation	20-03-09	CI
Motion for Asset Sale Filed by Aradigm Corporation	20-02-20	CI
Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	20-02-20	CI
Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	19-11-05	CI
Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	19-10-30	CI
Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	19-10-21	CI
Motion for Exclusivity Period Extension Approved For Aradigm Corporation	19-07-19	CI
First Motion for Exclusivity Period Extension Filed by Aradigm Corporation	19-06-14	CI
DIP Financing Approved for Aradigm Corporation	19-06-06	CI
Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019	19-02-22	CI
Aradigm Corporation will Change its Ticker to ARDM.Q from ARDM	19-02-20	CI
Aradigm Corporation Announces Management Changes	19-02-19	CI
Aradigm Corporation Filed for Bankruptcy	19-02-15	CI
Aradigm Intends To Sell Assets	19-02-15	CI
Aradigm Corporation Announces Detailed Third Party Evaluation Results for Apulmiq/Linhaliq	19-01-16	CI
Aradigm Corporation(OTCPK:ARDM) dropped from S&P TMI Index	19-01-16	CI
Aradigm Corporation(OTCPK:ARDM.Q) dropped from NASDAQ Composite Index	19-01-15	CI
Aradigm Corporation announced that it has received $4 million in funding from Grifols Worldwide Operations Ltd.	19-01-01	CI
Aradigm Announces Results of Third Party Verification for Apulmiq	18-12-20	CI

Chart Aradigm Corporation

Duration

Period

More charts

Company Profile

Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+23.13%	46.93B
LONZA GROUP AG	+37.49%	39.08B
IQVIA HOLDINGS INC.	-8.73%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	31.01B
CELLTRION, INC.	-12.26%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.57%	25.88B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+32.23%	12.53B
BIO-TECHNE CORPORATION	-6.56%	11.36B

Other Biotechnology & Medical Research